Regenxbio RGNX
NASDAQ RGNX
$7.40 +0.25 (+3.50%)
At close: Oct 20, 2026 · 4:00 PM EDT

Regenxbio (RGNX) Notes Payables (2014)

Updated

Regenxbio (RGNX) recorded Notes Payables of $2.4 million in Q4 2014.

Analysis

Regenxbio (RGNX) Notes Payables (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Regenxbio 391.13 Mn -541.96 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 2.40 Mn
API Access

Regenxbio Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=RGNX&period=max&api_key=YOUR_API_KEY